Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC.
Jing W, Xu T, Wu L, Lopez PB, Grassberger C, Ellsworth SG, Mohan R, Hobbs BP, Blumenschein GR, Tu J, Altan M, Lee P, Liao Z, Lin SH.
Jing W, et al. Among authors: lopez pb.
JTO Clin Res Rep. 2022 Aug 7;3(9):100391. doi: 10.1016/j.jtocrr.2022.100391. eCollection 2022 Sep.
JTO Clin Res Rep. 2022.
PMID: 36089921
Free PMC article.